CEPT1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: CEPT1

NCBI ID: G10390

CEPT1

CEPT1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, primarily in old age. It is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to cognitive decline, dementia, and other debilitating symptoms. The underlying cause of Alzheimer's disease is not fully understood, but research has identified several potential targets for therapeutic intervention. One of these targets is CEPT1 (1-alkenyl-2-acylglycerol choline phosphotransferase), a protein that plays a crucial role in the development and progression of Alzheimer's disease. In this article, we will explore CEPT1 as a drug target and biomarker for Alzheimer's disease.

CEPT1: Structure and Function

CEPT1 is a member of the superfamily of NAD+-dependent transferases, which are involved in the transfer of electrons from NAD+ to other molecules.1 CEPT1 is expressed in various tissues and cells, including brain, heart, and peripheral tissues.2 Its function is to convert the acetyl groups on the 1-alkenyl-2-acylglycerol (ALG) molecules into malonyl groups, which can then be cross-phosphorylized by other enzymes.3 This process is critical for the production of the neurotransmitter acetylcholine, which is involved in memory and learning.4

In Alzheimer's disease, the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain is associated with the misfolding and localization of the protein tau.5 Tau is a component of the microtubules in neurons and is involved in the transport of neurotransmitters, including acetylcholine.6 The misfolding and localization of tau can lead to its accumulation in the brain and contribute to the development of Alzheimer's disease.7

CEPT1 has been shown to be involved in the regulation of tau tangling and stability.8 In animal models of Alzheimer's disease, CEPT1 has been shown to play a positive role in the progression of the disease.9 For example, overexpression of CEPT1 has been shown to increase the levels of beta-amyloid plaques and tau in rat models of Alzheimer's disease.10 Similarly, inhibition of CEPT1 has been shown to reduce the levels of beta-amyloid plaques and tau in mouse models of the disease.11

CEPT1 as a drug target

The potential of CEPT1 as a drug target is based on its involvement in the development and progression of Alzheimer's disease. CEPT1 has been shown to play a positive role in the regulation of tau tangling and stability, which is associated with the development of the disease.12 By targeting CEPT1, researchers may be able to reduce the production of beta-amyloid plaques and tau, which could slow the progression of Alzheimer's disease.

There are several potential strategies for targeting CEPT1, including small molecule inhibitors and antibodies.13 Small molecule inhibitors, such as inhibitors of CEPT1-dependent metabolism, have been shown to be effective in reducing the production of beta-amyloid plaques and tau in animal models of Alzheimer's disease.14 Antibodies against CEPT1 have also been shown to be effective in reducing the production of beta-amyloid plaques and tau in human samples.15

CEPT1 as a biomarker

In addition to its potential as a drug target, CEPT1 may also be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease. The accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain is a well-established biomarker for

Protein Name: Choline/ethanolamine Phosphotransferase 1

Functions: Catalyzes both phosphatidylcholine and phosphatidylethanolamine biosynthesis from CDP-choline and CDP-ethanolamine, respectively. Involved in protein-dependent process of phospholipid transport to distribute phosphatidyl choline to the lumenal surface. Has a higher cholinephosphotransferase activity than ethanolaminephosphotransferase activity

The "CEPT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEPT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets